A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio® XT provided high value from a health economic perspective SAN FRANCISCO, Nov. 06, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and […]
Tag: Zio
IRHYTHM GAINS FDA CLEARANCE FOR ITS CLINICALLY INTEGRATED ZEUS SYSTEM
Developed in partnership with Verily, the Zio® Watch and the ZEUS System combine to create a clinical grade watch to detect and characterize AFib and integrate with clinician’s workflow SAN FRANCISCO, July 22, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital […]
Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF
New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillation Additional data shows that Zio AT can positively impact hospital resources – saving one healthcare system 136 inpatient […]
Zio® by iRhythm Shows Significantly Higher Documentation of Atrial Fibrillation and Atrial Flutter Compared to Holter Monitors, Event Monitors
Additional clinical research shows bradyarrhythmias can be detected with 14-day cardiac monitoring through Zio XT before and after TAVR SAN FRANCISCO, Feb. 28, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of […]
iRhythm® Technologies Continues to Fuel Innovation in Cardiac Monitoring and Unveils Two FDA Clearances for Superior Patient Care
The new Zio® monitor is designed to significantly improve patient comfort, while enhanced AI capabilities raise the bar on cardiac arrhythmia detection SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions […]
New Study Finds Zio by iRhythm 10x More Effective in Proactively Identifying Atrial Fibrillation and Increasing Detection
Wearable cardiac monitoring solution enables early detection and treatment of arrhythmia based on risk factors, according to results of the SCREEN-AF study published in JAMA Cardiology LONDON–(BUSINESS WIRE)–iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement […]
Zio by iRhythm Detects Previously Undiagnosed Atrial Fibrillation and Helps to Prevent Hospitalizations, Stroke, and Death as a Result
Three-Year Study Results Presented at 2020 American Heart Association Scientific Sessions Zio Supports Better Healthcare Utilization Rates and Patient Outcomes With Ambulatory Cardiac Monitoring SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health […]
Study Results Show Zio by iRhythm Improves Detection of Asymptomatic Atrial Fibrillation in At-Risk Population
SAN FRANCISCO, July 10, 2018 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that results of the mHealth Screening to Prevent Strokes (mSToPS) study, which […]
Zio by iRhythm Gains Further Recognition as Key Diagnostic Cardiac Monitoring System by US and UK Health Organizations
SAN FRANCISCO, April 10, 2017 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced the recent publication of two documents in support of extended continuous ambulatory monitoring for […]